Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | ABL1 | P00519 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | IDE | P14735 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.71 |
| ▸ | HLCS | P50747 | 6/20 | 0.64 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | NR2E3 | Q9Y5X4 | 2/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19170150 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL10047674 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL10047701 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL132274 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL10171691 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL19267509 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL20216901 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL21488759 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL20844951 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA | |
| SCHEMBL14617995 | 1.00 | TDP1 (1.00) | TDP1L3MBTL1MEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | SDG, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | SDG, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | SDG, INC. ( AN OHIO CORPORATION) (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100129428-A1 | SUPRA MOLECULAR CONSTRUCT FOR DELIVERY OF INTERFERON TO A MAMMAL | HAVCR2, IFNAR1, IFNG | TDP1 4713/4885L3MBTL1 3129/4885MEN1 4095/4885 |
| US-20090087479-A1 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | TDP1 4757/4885L3MBTL1 2707/4885MEN1 1343/4885 |
| US-20120035105-A1 | Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments | IAPP, IDE, INSR | TDP1 2829/4885L3MBTL1 4717/4885MEN1 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.